NCT00102895View on ClinicalTrials.gov

A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

September 30, 2005

Conditions
Breast NeoplasmsNeoplasm Metastasis
Interventions
DRUG

CP-724,714

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY